TEVA files Rule 144 to sell 16,195 Ordinary Shares

Teva Pharmaceutical Industries Limited filed a Rule 144 notice reporting proposed sales of 16,195 Ordinary Shares.

Accepted by SEC EDGAR 06/03/2026 - 03:59 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited filed a Rule 144 notice reporting proposed sales of 16,195 Ordinary Shares. The filing lists the securities as resulting from a Restricted Share Unit award vesting with an execution date shown as 06/03/2026. The excerpt also records a prior sale of 17,295 shares on 03/05/2026 for $547,704.98.

Insights

Securities Counsel

Rule 144 notice for proposed resale of vested shares; prior open-market sale noted.

The filing lists 16,195 Ordinary Shares to be sold tied to a Restricted Share Unit award vesting dated 06/03/2026. It also discloses a prior sale of 17,295 shares on 03/05/2026 for $547,704.98.

These entries are procedural disclosures under Rule 144 describing intended resale and a recent disposition. Cash‑flow treatment and broker details are stated in the excerpt; timing and method beyond the listed dates are not further detailed in the provided content.

Key Figures

Shares proposed for resale: 16,195 shares Shares sold in past 3 months: 17,295 shares Proceeds from prior sale: $547,704.98 +1 more

4 metrics

Shares proposed for resale 16,195 shares listed as Securities To Be Sold, <date>06/03/2026</date>

Shares sold in past 3 months 17,295 shares sale by Shields Matthew on <date>03/05/2026</date>

Proceeds from prior sale $547,704.98 gross proceeds reported for 17,295-share sale on <date>03/05/2026</date>

Broker listed Citigroup Global Markets listing in Securities Information table

Key Terms

Rule 144, Restricted Share Unit award vesting, Ordinary Shares

3 terms

Rule 144 regulatory

"Securities To Be Sold table referencing a Rule 144 notice"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Share Unit award vesting financial

"RESTRICTED SHARE UNIT AWARD VESTING entry associated with the 16,195 shares"

Ordinary Shares financial

"Repeated label 'ORDINARY SHARES' in the Securities Information rows"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does TEVA's Form 144 report?

The Form 144 reports a proposed resale of 16,195 Ordinary Shares linked to a Restricted Share Unit vesting dated 06/03/2026. It also shows a prior sale of 17,295 shares on 03/05/2026 for $547,704.98.

Who is listed as having sold shares in the past three months for TEVA?

The excerpt lists Shields Matthew as having sold 17,295 Ordinary Shares on 03/05/2026, producing proceeds of $547,704.98. The filing provides the sale date and gross proceeds in the table.

Are the shares to be sold restricted or vested for TEVA?

The filing ties the 16,195 Ordinary Shares to a Restricted Share Unit award vesting with the vesting/execution date shown as 06/03/2026. The entry identifies the award type as compensation-related.

Does the Form 144 specify how the TEVA shares will be sold?

The provided excerpt lists the shares to be sold and a broker reference (Citigroup Global Markets), but it does not detail the specific sale method beyond the table entries. Further distribution mechanics are not included in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002025621
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Shields Matthew
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EXECUTIVE VP TEVA GLOBAL OPERATIONS

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	16195	532329.65	1164426972	06/03/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	06/03/2024	RESTRICTED SHARE UNIT AWARD VESTING	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			16195	06/03/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shields Matthew TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/05/2026	17295	547704.98

144: Remarks and Signature

Remarks	SECTION 3 E BASED ON ORDINARY SHARES. SALES WERE PERFORMED AS PART OF AN ESTABLISHED 10B51 PLAN ADOPTED IN NOVEMBER 2025
Date of Notice	06/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)